膵臓内分泌腫瘍（PNET）治療薬のグローバル市場インサイト・予測（～2028年）

• 英文タイトル：Global Pancreatic Endocrine Tumor Drug Market Insights and Forecast to 2028

• レポートコード：QY2203B14340
• 出版社/出版日：QYResearch / 2022年3月
• レポート形態：英文、PDF、90ページ
• 納品方法：Eメール（納期：3日）
• 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥735,000 (USD4,900)	▷ お問い合わせ
Multi User	￥1,102,500 (USD7,350)	▷ お問い合わせ
Enterprise License	￥1,470,000 (USD9,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

新型コロナウイルス感染症のパンデミックにより、世界の膵臓内分泌腫瘍（PNET）治療薬の市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に膵臓内分泌腫瘍（PNET）治療薬の世界市場のxxx％を占める「ブパルリシブ塩酸塩」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「クリニック」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。
中国の膵臓内分泌腫瘍（PNET）治療薬の市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパの膵臓内分泌腫瘍（PNET）治療薬市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパの膵臓内分泌腫瘍（PNET）治療薬市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。

膵臓内分泌腫瘍（PNET）治療薬のグローバル主要メーカーには、Ipsen S.A.、Jiangsu Hengrui Medicine Co., Ltd.、MediaPharma s.r.l.、Novartis AG、OXiGENE, Inc.などがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。

膵臓内分泌腫瘍（PNET）治療薬市場は、種類と用途によって区分されます。世界の膵臓内分泌腫瘍（PNET）治療薬市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。

【種類別セグメント】
ブパルリシブ塩酸塩、ドビチニブ乳酸塩、フォスブレタブリン・トロメタミン、ランレオチド酢酸塩、MPHE-001B、その他

【用途別セグメント】
クリニック、研究所、病院

【掲載地域】
北米：アメリカ、カナダ
ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア
中南米：メキシコ、ブラジル、アルゼンチン
中東・アフリカ：トルコ、サウジアラビア、UAE

【目次（一部）】

・調査の範囲
- 膵臓内分泌腫瘍（PNET）治療薬製品概要
- 種類別市場（ブパルリシブ塩酸塩、ドビチニブ乳酸塩、フォスブレタブリン・トロメタミン、ランレオチド酢酸塩、MPHE-001B、その他）
- 用途別市場（クリニック、研究所、病院）
- 調査の目的
・エグゼクティブサマリー
- 世界の膵臓内分泌腫瘍（PNET）治療薬販売量予測2017-2028
- 世界の膵臓内分泌腫瘍（PNET）治療薬売上予測2017-2028
- 膵臓内分泌腫瘍（PNET）治療薬の地域別販売量
- 膵臓内分泌腫瘍（PNET）治療薬の地域別売上
- 北米市場
- ヨーロッパ市場
- アジア太平洋市場
- 中南米市場
- 中東・アフリカ市場
・メーカーの競争状況
- 主要メーカー別膵臓内分泌腫瘍（PNET）治療薬販売量
- 主要メーカー別膵臓内分泌腫瘍（PNET）治療薬売上
- 主要メーカー別膵臓内分泌腫瘍（PNET）治療薬価格
- 競争状況の分析
- 企業M&A動向
・種類別市場規模（ブパルリシブ塩酸塩、ドビチニブ乳酸塩、フォスブレタブリン・トロメタミン、ランレオチド酢酸塩、MPHE-001B、その他）
- 膵臓内分泌腫瘍（PNET）治療薬の種類別販売量
- 膵臓内分泌腫瘍（PNET）治療薬の種類別売上
- 膵臓内分泌腫瘍（PNET）治療薬の種類別価格
・用途別市場規模（クリニック、研究所、病院）
- 膵臓内分泌腫瘍（PNET）治療薬の用途別販売量
- 膵臓内分泌腫瘍（PNET）治療薬の用途別売上
- 膵臓内分泌腫瘍（PNET）治療薬の用途別価格
・北米市場
- 北米の膵臓内分泌腫瘍（PNET）治療薬市場規模（種類別、用途別）
- 主要国別の膵臓内分泌腫瘍（PNET）治療薬市場規模（アメリカ、カナダ）
・ヨーロッパ市場
- ヨーロッパの膵臓内分泌腫瘍（PNET）治療薬市場規模（種類別、用途別）
- 主要国別の膵臓内分泌腫瘍（PNET）治療薬市場規模（ドイツ、フランス、イギリス、イタリア、ロシア）
・アジア太平洋市場
- アジア太平洋の膵臓内分泌腫瘍（PNET）治療薬市場規模（種類別、用途別）
- 主要国別の膵臓内分泌腫瘍（PNET）治療薬市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア）
・中南米市場
- 中南米の膵臓内分泌腫瘍（PNET）治療薬市場規模（種類別、用途別）
- 主要国別の膵臓内分泌腫瘍（PNET）治療薬市場規模（メキシコ、ブラジル、アルゼンチン）
・中東・アフリカ市場
- 中東・アフリカの膵臓内分泌腫瘍（PNET）治療薬市場規模（種類別、用途別）
- 主要国別の膵臓内分泌腫瘍（PNET）治療薬市場規模（トルコ、サウジアラビア）
・企業情報
Ipsen S.A.、Jiangsu Hengrui Medicine Co., Ltd.、MediaPharma s.r.l.、Novartis AG、OXiGENE, Inc.
・産業チェーン及び販売チャネル分析
- 膵臓内分泌腫瘍（PNET）治療薬の産業チェーン分析
- 膵臓内分泌腫瘍（PNET）治療薬の原材料
- 膵臓内分泌腫瘍（PNET）治療薬の生産プロセス
- 膵臓内分泌腫瘍（PNET）治療薬の販売及びマーケティング
- 膵臓内分泌腫瘍（PNET）治療薬の主要顧客
・マーケットドライバー、機会、課題、リスク要因分析
- 膵臓内分泌腫瘍（PNET）治療薬の産業動向
- 膵臓内分泌腫瘍（PNET）治療薬のマーケットドライバー
- 膵臓内分泌腫瘍（PNET）治療薬の課題
- 膵臓内分泌腫瘍（PNET）治療薬の阻害要因
・主な調査結果

Market Analysis and Insights: Global Pancreatic Endocrine Tumor Drug Market
Due to the COVID-19 pandemic, the global Pancreatic Endocrine Tumor Drug market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, Buparlisib Hydrochloride accounting for % of the Pancreatic Endocrine Tumor Drug global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Clinic segment is altered to an % CAGR throughout this forecast period.
China Pancreatic Endocrine Tumor Drug market size is valued at US$ million in 2021, while the US and Europe Pancreatic Endocrine Tumor Drug are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Pancreatic Endocrine Tumor Drug landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Pancreatic Endocrine Tumor Drug include Ipsen S.A., Jiangsu Hengrui Medicine Co., Ltd., MediaPharma s.r.l., Novartis AG and OXiGENE, Inc., etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Pancreatic Endocrine Tumor Drug Scope and Segment
Pancreatic Endocrine Tumor Drug market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Pancreatic Endocrine Tumor Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Buparlisib Hydrochloride
Dovitinib Lactate
Fosbretabulin Tromethamine
Lanreotide Acetate
MPHE-001B
Others
Segment by Application
Clinic
Research Center
Hospital
By Company
Ipsen S.A.
Jiangsu Hengrui Medicine Co., Ltd.
MediaPharma s.r.l.
Novartis AG
OXiGENE, Inc.
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E

レポート目次

1 Study Coverage
1.1 Pancreatic Endocrine Tumor Drug Product Introduction
1.2 Market by Type
1.2.1 Global Pancreatic Endocrine Tumor Drug Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Buparlisib Hydrochloride
1.2.3 Dovitinib Lactate
1.2.4 Fosbretabulin Tromethamine
1.2.5 Lanreotide Acetate
1.2.6 MPHE-001B
1.2.7 Others
1.3 Market by Application
1.3.1 Global Pancreatic Endocrine Tumor Drug Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Clinic
1.3.3 Research Center
1.3.4 Hospital
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Pancreatic Endocrine Tumor Drug Sales Estimates and Forecasts 2017-2028
2.2 Global Pancreatic Endocrine Tumor Drug Revenue Estimates and Forecasts 2017-2028
2.3 Global Pancreatic Endocrine Tumor Drug Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Pancreatic Endocrine Tumor Drug Sales by Region
2.4.1 Global Pancreatic Endocrine Tumor Drug Sales by Region (2017-2022)
2.4.2 Global Sales Pancreatic Endocrine Tumor Drug by Region (2023-2028)
2.5 Global Pancreatic Endocrine Tumor Drug Revenue by Region
2.5.1 Global Pancreatic Endocrine Tumor Drug Revenue by Region (2017-2022)
2.5.2 Global Pancreatic Endocrine Tumor Drug Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Pancreatic Endocrine Tumor Drug Sales by Manufacturers
3.1.1 Global Top Pancreatic Endocrine Tumor Drug Manufacturers by Sales (2017-2022)
3.1.2 Global Pancreatic Endocrine Tumor Drug Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Pancreatic Endocrine Tumor Drug in 2021
3.2 Global Pancreatic Endocrine Tumor Drug Revenue by Manufacturers
3.2.1 Global Pancreatic Endocrine Tumor Drug Revenue by Manufacturers (2017-2022)
3.2.2 Global Pancreatic Endocrine Tumor Drug Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Pancreatic Endocrine Tumor Drug Revenue in 2021
3.3 Global Pancreatic Endocrine Tumor Drug Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Pancreatic Endocrine Tumor Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Pancreatic Endocrine Tumor Drug Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Pancreatic Endocrine Tumor Drug Sales by Type
4.1.1 Global Pancreatic Endocrine Tumor Drug Historical Sales by Type (2017-2022)
4.1.2 Global Pancreatic Endocrine Tumor Drug Forecasted Sales by Type (2023-2028)
4.1.3 Global Pancreatic Endocrine Tumor Drug Sales Market Share by Type (2017-2028)
4.2 Global Pancreatic Endocrine Tumor Drug Revenue by Type
4.2.1 Global Pancreatic Endocrine Tumor Drug Historical Revenue by Type (2017-2022)
4.2.2 Global Pancreatic Endocrine Tumor Drug Forecasted Revenue by Type (2023-2028)
4.2.3 Global Pancreatic Endocrine Tumor Drug Revenue Market Share by Type (2017-2028)
4.3 Global Pancreatic Endocrine Tumor Drug Price by Type
4.3.1 Global Pancreatic Endocrine Tumor Drug Price by Type (2017-2022)
4.3.2 Global Pancreatic Endocrine Tumor Drug Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Pancreatic Endocrine Tumor Drug Sales by Application
5.1.1 Global Pancreatic Endocrine Tumor Drug Historical Sales by Application (2017-2022)
5.1.2 Global Pancreatic Endocrine Tumor Drug Forecasted Sales by Application (2023-2028)
5.1.3 Global Pancreatic Endocrine Tumor Drug Sales Market Share by Application (2017-2028)
5.2 Global Pancreatic Endocrine Tumor Drug Revenue by Application
5.2.1 Global Pancreatic Endocrine Tumor Drug Historical Revenue by Application (2017-2022)
5.2.2 Global Pancreatic Endocrine Tumor Drug Forecasted Revenue by Application (2023-2028)
5.2.3 Global Pancreatic Endocrine Tumor Drug Revenue Market Share by Application (2017-2028)
5.3 Global Pancreatic Endocrine Tumor Drug Price by Application
5.3.1 Global Pancreatic Endocrine Tumor Drug Price by Application (2017-2022)
5.3.2 Global Pancreatic Endocrine Tumor Drug Price Forecast by Application (2023-2028)
6 North America
6.1 North America Pancreatic Endocrine Tumor Drug Market Size by Type
6.1.1 North America Pancreatic Endocrine Tumor Drug Sales by Type (2017-2028)
6.1.2 North America Pancreatic Endocrine Tumor Drug Revenue by Type (2017-2028)
6.2 North America Pancreatic Endocrine Tumor Drug Market Size by Application
6.2.1 North America Pancreatic Endocrine Tumor Drug Sales by Application (2017-2028)
6.2.2 North America Pancreatic Endocrine Tumor Drug Revenue by Application (2017-2028)
6.3 North America Pancreatic Endocrine Tumor Drug Market Size by Country
6.3.1 North America Pancreatic Endocrine Tumor Drug Sales by Country (2017-2028)
6.3.2 North America Pancreatic Endocrine Tumor Drug Revenue by Country (2017-2028)
6.3.3 U.S.
6.3.4 Canada
7 Europe
7.1 Europe Pancreatic Endocrine Tumor Drug Market Size by Type
7.1.1 Europe Pancreatic Endocrine Tumor Drug Sales by Type (2017-2028)
7.1.2 Europe Pancreatic Endocrine Tumor Drug Revenue by Type (2017-2028)
7.2 Europe Pancreatic Endocrine Tumor Drug Market Size by Application
7.2.1 Europe Pancreatic Endocrine Tumor Drug Sales by Application (2017-2028)
7.2.2 Europe Pancreatic Endocrine Tumor Drug Revenue by Application (2017-2028)
7.3 Europe Pancreatic Endocrine Tumor Drug Market Size by Country
7.3.1 Europe Pancreatic Endocrine Tumor Drug Sales by Country (2017-2028)
7.3.2 Europe Pancreatic Endocrine Tumor Drug Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Pancreatic Endocrine Tumor Drug Market Size by Type
8.1.1 Asia Pacific Pancreatic Endocrine Tumor Drug Sales by Type (2017-2028)
8.1.2 Asia Pacific Pancreatic Endocrine Tumor Drug Revenue by Type (2017-2028)
8.2 Asia Pacific Pancreatic Endocrine Tumor Drug Market Size by Application
8.2.1 Asia Pacific Pancreatic Endocrine Tumor Drug Sales by Application (2017-2028)
8.2.2 Asia Pacific Pancreatic Endocrine Tumor Drug Revenue by Application (2017-2028)
8.3 Asia Pacific Pancreatic Endocrine Tumor Drug Market Size by Region
8.3.1 Asia Pacific Pancreatic Endocrine Tumor Drug Sales by Region (2017-2028)
8.3.2 Asia Pacific Pancreatic Endocrine Tumor Drug Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
8.3.12 Philippines
9 Latin America
9.1 Latin America Pancreatic Endocrine Tumor Drug Market Size by Type
9.1.1 Latin America Pancreatic Endocrine Tumor Drug Sales by Type (2017-2028)
9.1.2 Latin America Pancreatic Endocrine Tumor Drug Revenue by Type (2017-2028)
9.2 Latin America Pancreatic Endocrine Tumor Drug Market Size by Application
9.2.1 Latin America Pancreatic Endocrine Tumor Drug Sales by Application (2017-2028)
9.2.2 Latin America Pancreatic Endocrine Tumor Drug Revenue by Application (2017-2028)
9.3 Latin America Pancreatic Endocrine Tumor Drug Market Size by Country
9.3.1 Latin America Pancreatic Endocrine Tumor Drug Sales by Country (2017-2028)
9.3.2 Latin America Pancreatic Endocrine Tumor Drug Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Pancreatic Endocrine Tumor Drug Market Size by Type
10.1.1 Middle East and Africa Pancreatic Endocrine Tumor Drug Sales by Type (2017-2028)
10.1.2 Middle East and Africa Pancreatic Endocrine Tumor Drug Revenue by Type (2017-2028)
10.2 Middle East and Africa Pancreatic Endocrine Tumor Drug Market Size by Application
10.2.1 Middle East and Africa Pancreatic Endocrine Tumor Drug Sales by Application (2017-2028)
10.2.2 Middle East and Africa Pancreatic Endocrine Tumor Drug Revenue by Application (2017-2028)
10.3 Middle East and Africa Pancreatic Endocrine Tumor Drug Market Size by Country
10.3.1 Middle East and Africa Pancreatic Endocrine Tumor Drug Sales by Country (2017-2028)
10.3.2 Middle East and Africa Pancreatic Endocrine Tumor Drug Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Ipsen S.A.
11.1.1 Ipsen S.A. Corporation Information
11.1.2 Ipsen S.A. Overview
11.1.3 Ipsen S.A. Pancreatic Endocrine Tumor Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Ipsen S.A. Pancreatic Endocrine Tumor Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Ipsen S.A. Recent Developments
11.2 Jiangsu Hengrui Medicine Co., Ltd.
11.2.1 Jiangsu Hengrui Medicine Co., Ltd. Corporation Information
11.2.2 Jiangsu Hengrui Medicine Co., Ltd. Overview
11.2.3 Jiangsu Hengrui Medicine Co., Ltd. Pancreatic Endocrine Tumor Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Jiangsu Hengrui Medicine Co., Ltd. Pancreatic Endocrine Tumor Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Jiangsu Hengrui Medicine Co., Ltd. Recent Developments
11.3 MediaPharma s.r.l.
11.3.1 MediaPharma s.r.l. Corporation Information
11.3.2 MediaPharma s.r.l. Overview
11.3.3 MediaPharma s.r.l. Pancreatic Endocrine Tumor Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 MediaPharma s.r.l. Pancreatic Endocrine Tumor Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 MediaPharma s.r.l. Recent Developments
11.4 Novartis AG
11.4.1 Novartis AG Corporation Information
11.4.2 Novartis AG Overview
11.4.3 Novartis AG Pancreatic Endocrine Tumor Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Novartis AG Pancreatic Endocrine Tumor Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Novartis AG Recent Developments
11.5 OXiGENE, Inc.
11.5.1 OXiGENE, Inc. Corporation Information
11.5.2 OXiGENE, Inc. Overview
11.5.3 OXiGENE, Inc. Pancreatic Endocrine Tumor Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 OXiGENE, Inc. Pancreatic Endocrine Tumor Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 OXiGENE, Inc. Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Pancreatic Endocrine Tumor Drug Industry Chain Analysis
12.2 Pancreatic Endocrine Tumor Drug Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Pancreatic Endocrine Tumor Drug Production Mode & Process
12.4 Pancreatic Endocrine Tumor Drug Sales and Marketing
12.4.1 Pancreatic Endocrine Tumor Drug Sales Channels
12.4.2 Pancreatic Endocrine Tumor Drug Distributors
12.5 Pancreatic Endocrine Tumor Drug Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Pancreatic Endocrine Tumor Drug Industry Trends
13.2 Pancreatic Endocrine Tumor Drug Market Drivers
13.3 Pancreatic Endocrine Tumor Drug Market Challenges
13.4 Pancreatic Endocrine Tumor Drug Market Restraints
14 Key Findings in The Global Pancreatic Endocrine Tumor Drug Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Tables
Table 1. Global Pancreatic Endocrine Tumor Drug Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of Buparlisib Hydrochloride
Table 3. Major Manufacturers of Dovitinib Lactate
Table 4. Major Manufacturers of Fosbretabulin Tromethamine
Table 5. Major Manufacturers of Lanreotide Acetate
Table 6. Major Manufacturers of MPHE-001B
Table 7. Major Manufacturers of Others
Table 8. Global Pancreatic Endocrine Tumor Drug Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 9. Global Pancreatic Endocrine Tumor Drug Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
Table 10. Global Pancreatic Endocrine Tumor Drug Sales by Region (2017-2022) & (K Pcs)
Table 11. Global Pancreatic Endocrine Tumor Drug Sales Market Share by Region (2017-2022)
Table 12. Global Pancreatic Endocrine Tumor Drug Sales by Region (2023-2028) & (K Pcs)
Table 13. Global Pancreatic Endocrine Tumor Drug Sales Market Share by Region (2023-2028)
Table 14. Global Pancreatic Endocrine Tumor Drug Revenue by Region (2017-2022) & (US$ Million)
Table 15. Global Pancreatic Endocrine Tumor Drug Revenue Market Share by Region (2017-2022)
Table 16. Global Pancreatic Endocrine Tumor Drug Revenue by Region (2023-2028) & (US$ Million)
Table 17. Global Pancreatic Endocrine Tumor Drug Revenue Market Share by Region (2023-2028)
Table 18. Global Pancreatic Endocrine Tumor Drug Sales by Manufacturers (2017-2022) & (K Pcs)
Table 19. Global Pancreatic Endocrine Tumor Drug Sales Share by Manufacturers (2017-2022)
Table 20. Global Pancreatic Endocrine Tumor Drug Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 21. Global Pancreatic Endocrine Tumor Drug Revenue Share by Manufacturers (2017-2022)
Table 22. Pancreatic Endocrine Tumor Drug Price by Manufacturers (2017-2022) &(USD/Pcs)
Table 23. Global Pancreatic Endocrine Tumor Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 24. Global Pancreatic Endocrine Tumor Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pancreatic Endocrine Tumor Drug as of 2021)
Table 25. Pancreatic Endocrine Tumor Drug Manufacturing Base Distribution and Headquarters
Table 26. Manufacturers Pancreatic Endocrine Tumor Drug Product Offered
Table 27. Date of Manufacturers Enter into Pancreatic Endocrine Tumor Drug Market
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Pancreatic Endocrine Tumor Drug Sales by Type (2017-2022) & (K Pcs)
Table 30. Global Pancreatic Endocrine Tumor Drug Sales by Type (2023-2028) & (K Pcs)
Table 31. Global Pancreatic Endocrine Tumor Drug Sales Share by Type (2017-2022)
Table 32. Global Pancreatic Endocrine Tumor Drug Sales Share by Type (2023-2028)
Table 33. Global Pancreatic Endocrine Tumor Drug Revenue by Type (2017-2022) & (US$ Million)
Table 34. Global Pancreatic Endocrine Tumor Drug Revenue by Type (2023-2028) & (US$ Million)
Table 35. Global Pancreatic Endocrine Tumor Drug Revenue Share by Type (2017-2022)
Table 36. Global Pancreatic Endocrine Tumor Drug Revenue Share by Type (2023-2028)
Table 37. Pancreatic Endocrine Tumor Drug Price by Type (2017-2022) & (USD/Pcs)
Table 38. Global Pancreatic Endocrine Tumor Drug Price Forecast by Type (2023-2028) & (USD/Pcs)
Table 39. Global Pancreatic Endocrine Tumor Drug Sales by Application (2017-2022) & (K Pcs)
Table 40. Global Pancreatic Endocrine Tumor Drug Sales by Application (2023-2028) & (K Pcs)
Table 41. Global Pancreatic Endocrine Tumor Drug Sales Share by Application (2017-2022)
Table 42. Global Pancreatic Endocrine Tumor Drug Sales Share by Application (2023-2028)
Table 43. Global Pancreatic Endocrine Tumor Drug Revenue by Application (2017-2022) & (US$ Million)
Table 44. Global Pancreatic Endocrine Tumor Drug Revenue by Application (2023-2028) & (US$ Million)
Table 45. Global Pancreatic Endocrine Tumor Drug Revenue Share by Application (2017-2022)
Table 46. Global Pancreatic Endocrine Tumor Drug Revenue Share by Application (2023-2028)
Table 47. Pancreatic Endocrine Tumor Drug Price by Application (2017-2022) & (USD/Pcs)
Table 48. Global Pancreatic Endocrine Tumor Drug Price Forecast by Application (2023-2028) & (USD/Pcs)
Table 49. North America Pancreatic Endocrine Tumor Drug Sales by Type (2017-2022) & (K Pcs)
Table 50. North America Pancreatic Endocrine Tumor Drug Sales by Type (2023-2028) & (K Pcs)
Table 51. North America Pancreatic Endocrine Tumor Drug Revenue by Type (2017-2022) & (US$ Million)
Table 52. North America Pancreatic Endocrine Tumor Drug Revenue by Type (2023-2028) & (US$ Million)
Table 53. North America Pancreatic Endocrine Tumor Drug Sales by Application (2017-2022) & (K Pcs)
Table 54. North America Pancreatic Endocrine Tumor Drug Sales by Application (2023-2028) & (K Pcs)
Table 55. North America Pancreatic Endocrine Tumor Drug Revenue by Application (2017-2022) & (US$ Million)
Table 56. North America Pancreatic Endocrine Tumor Drug Revenue by Application (2023-2028) & (US$ Million)
Table 57. North America Pancreatic Endocrine Tumor Drug Sales by Country (2017-2022) & (K Pcs)
Table 58. North America Pancreatic Endocrine Tumor Drug Sales by Country (2023-2028) & (K Pcs)
Table 59. North America Pancreatic Endocrine Tumor Drug Revenue by Country (2017-2022) & (US$ Million)
Table 60. North America Pancreatic Endocrine Tumor Drug Revenue by Country (2023-2028) & (US$ Million)
Table 61. Europe Pancreatic Endocrine Tumor Drug Sales by Type (2017-2022) & (K Pcs)
Table 62. Europe Pancreatic Endocrine Tumor Drug Sales by Type (2023-2028) & (K Pcs)
Table 63. Europe Pancreatic Endocrine Tumor Drug Revenue by Type (2017-2022) & (US$ Million)
Table 64. Europe Pancreatic Endocrine Tumor Drug Revenue by Type (2023-2028) & (US$ Million)
Table 65. Europe Pancreatic Endocrine Tumor Drug Sales by Application (2017-2022) & (K Pcs)
Table 66. Europe Pancreatic Endocrine Tumor Drug Sales by Application (2023-2028) & (K Pcs)
Table 67. Europe Pancreatic Endocrine Tumor Drug Revenue by Application (2017-2022) & (US$ Million)
Table 68. Europe Pancreatic Endocrine Tumor Drug Revenue by Application (2023-2028) & (US$ Million)
Table 69. Europe Pancreatic Endocrine Tumor Drug Sales by Country (2017-2022) & (K Pcs)
Table 70. Europe Pancreatic Endocrine Tumor Drug Sales by Country (2023-2028) & (K Pcs)
Table 71. Europe Pancreatic Endocrine Tumor Drug Revenue by Country (2017-2022) & (US$ Million)
Table 72. Europe Pancreatic Endocrine Tumor Drug Revenue by Country (2023-2028) & (US$ Million)
Table 73. Asia Pacific Pancreatic Endocrine Tumor Drug Sales by Type (2017-2022) & (K Pcs)
Table 74. Asia Pacific Pancreatic Endocrine Tumor Drug Sales by Type (2023-2028) & (K Pcs)
Table 75. Asia Pacific Pancreatic Endocrine Tumor Drug Revenue by Type (2017-2022) & (US$ Million)
Table 76. Asia Pacific Pancreatic Endocrine Tumor Drug Revenue by Type (2023-2028) & (US$ Million)
Table 77. Asia Pacific Pancreatic Endocrine Tumor Drug Sales by Application (2017-2022) & (K Pcs)
Table 78. Asia Pacific Pancreatic Endocrine Tumor Drug Sales by Application (2023-2028) & (K Pcs)
Table 79. Asia Pacific Pancreatic Endocrine Tumor Drug Revenue by Application (2017-2022) & (US$ Million)
Table 80. Asia Pacific Pancreatic Endocrine Tumor Drug Revenue by Application (2023-2028) & (US$ Million)
Table 81. Asia Pacific Pancreatic Endocrine Tumor Drug Sales by Region (2017-2022) & (K Pcs)
Table 82. Asia Pacific Pancreatic Endocrine Tumor Drug Sales by Region (2023-2028) & (K Pcs)
Table 83. Asia Pacific Pancreatic Endocrine Tumor Drug Revenue by Region (2017-2022) & (US$ Million)
Table 84. Asia Pacific Pancreatic Endocrine Tumor Drug Revenue by Region (2023-2028) & (US$ Million)
Table 85. Latin America Pancreatic Endocrine Tumor Drug Sales by Type (2017-2022) & (K Pcs)
Table 86. Latin America Pancreatic Endocrine Tumor Drug Sales by Type (2023-2028) & (K Pcs)
Table 87. Latin America Pancreatic Endocrine Tumor Drug Revenue by Type (2017-2022) & (US$ Million)
Table 88. Latin America Pancreatic Endocrine Tumor Drug Revenue by Type (2023-2028) & (US$ Million)
Table 89. Latin America Pancreatic Endocrine Tumor Drug Sales by Application (2017-2022) & (K Pcs)
Table 90. Latin America Pancreatic Endocrine Tumor Drug Sales by Application (2023-2028) & (K Pcs)
Table 91. Latin America Pancreatic Endocrine Tumor Drug Revenue by Application (2017-2022) & (US$ Million)
Table 92. Latin America Pancreatic Endocrine Tumor Drug Revenue by Application (2023-2028) & (US$ Million)
Table 93. Latin America Pancreatic Endocrine Tumor Drug Sales by Country (2017-2022) & (K Pcs)
Table 94. Latin America Pancreatic Endocrine Tumor Drug Sales by Country (2023-2028) & (K Pcs)
Table 95. Latin America Pancreatic Endocrine Tumor Drug Revenue by Country (2017-2022) & (US$ Million)
Table 96. Latin America Pancreatic Endocrine Tumor Drug Revenue by Country (2023-2028) & (US$ Million)
Table 97. Middle East and Africa Pancreatic Endocrine Tumor Drug Sales by Type (2017-2022) & (K Pcs)
Table 98. Middle East and Africa Pancreatic Endocrine Tumor Drug Sales by Type (2023-2028) & (K Pcs)
Table 99. Middle East and Africa Pancreatic Endocrine Tumor Drug Revenue by Type (2017-2022) & (US$ Million)
Table 100. Middle East and Africa Pancreatic Endocrine Tumor Drug Revenue by Type (2023-2028) & (US$ Million)
Table 101. Middle East and Africa Pancreatic Endocrine Tumor Drug Sales by Application (2017-2022) & (K Pcs)
Table 102. Middle East and Africa Pancreatic Endocrine Tumor Drug Sales by Application (2023-2028) & (K Pcs)
Table 103. Middle East and Africa Pancreatic Endocrine Tumor Drug Revenue by Application (2017-2022) & (US$ Million)
Table 104. Middle East and Africa Pancreatic Endocrine Tumor Drug Revenue by Application (2023-2028) & (US$ Million)
Table 105. Middle East and Africa Pancreatic Endocrine Tumor Drug Sales by Country (2017-2022) & (K Pcs)
Table 106. Middle East and Africa Pancreatic Endocrine Tumor Drug Sales by Country (2023-2028) & (K Pcs)
Table 107. Middle East and Africa Pancreatic Endocrine Tumor Drug Revenue by Country (2017-2022) & (US$ Million)
Table 108. Middle East and Africa Pancreatic Endocrine Tumor Drug Revenue by Country (2023-2028) & (US$ Million)
Table 109. Ipsen S.A. Corporation Information
Table 110. Ipsen S.A. Description and Major Businesses
Table 111. Ipsen S.A. Pancreatic Endocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 112. Ipsen S.A. Pancreatic Endocrine Tumor Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 113. Ipsen S.A. Recent Developments
Table 114. Jiangsu Hengrui Medicine Co., Ltd. Corporation Information
Table 115. Jiangsu Hengrui Medicine Co., Ltd. Description and Major Businesses
Table 116. Jiangsu Hengrui Medicine Co., Ltd. Pancreatic Endocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 117. Jiangsu Hengrui Medicine Co., Ltd. Pancreatic Endocrine Tumor Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 118. Jiangsu Hengrui Medicine Co., Ltd. Recent Developments
Table 119. MediaPharma s.r.l. Corporation Information
Table 120. MediaPharma s.r.l. Description and Major Businesses
Table 121. MediaPharma s.r.l. Pancreatic Endocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 122. MediaPharma s.r.l. Pancreatic Endocrine Tumor Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 123. MediaPharma s.r.l. Recent Developments
Table 124. Novartis AG Corporation Information
Table 125. Novartis AG Description and Major Businesses
Table 126. Novartis AG Pancreatic Endocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 127. Novartis AG Pancreatic Endocrine Tumor Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 128. Novartis AG Recent Developments
Table 129. OXiGENE, Inc. Corporation Information
Table 130. OXiGENE, Inc. Description and Major Businesses
Table 131. OXiGENE, Inc. Pancreatic Endocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 132. OXiGENE, Inc. Pancreatic Endocrine Tumor Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 133. OXiGENE, Inc. Recent Developments
Table 134. Key Raw Materials Lists
Table 135. Raw Materials Key Suppliers Lists
Table 136. Pancreatic Endocrine Tumor Drug Distributors List
Table 137. Pancreatic Endocrine Tumor Drug Customers List
Table 138. Pancreatic Endocrine Tumor Drug Market Trends
Table 139. Pancreatic Endocrine Tumor Drug Market Drivers
Table 140. Pancreatic Endocrine Tumor Drug Market Challenges
Table 141. Pancreatic Endocrine Tumor Drug Market Restraints
Table 142. Research Programs/Design for This Report
Table 143. Key Data Information from Secondary Sources
Table 144. Key Data Information from Primary Sources
List of Figures
Figure 1. Pancreatic Endocrine Tumor Drug Product Picture
Figure 3. Global Pancreatic Endocrine Tumor Drug Market Share by Type in 2021 & 2028
Figure 3. Buparlisib Hydrochloride Product Picture
Figure 4. Dovitinib Lactate Product Picture
Figure 5. Fosbretabulin Tromethamine Product Picture
Figure 6. Lanreotide Acetate Product Picture
Figure 7. MPHE-001B Product Picture
Figure 8. Others Product Picture
Figure 9. Global Pancreatic Endocrine Tumor Drug Market Share by Application in 2021 & 2028
Figure 10. Clinic
Figure 11. Research Center
Figure 12. Hospital
Figure 13. Pancreatic Endocrine Tumor Drug Report Years Considered
Figure 14. Global Pancreatic Endocrine Tumor Drug Sales 2017-2028 (K Pcs)
Figure 15. Global Pancreatic Endocrine Tumor Drug Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 16. Global Pancreatic Endocrine Tumor Drug Revenue 2017-2028 (US$ Million)
Figure 17. Global Pancreatic Endocrine Tumor Drug Revenue Market Share by Region in Percentage: 2021 Versus 2028
Figure 18. Global Pancreatic Endocrine Tumor Drug Sales Market Share by Region (2017-2022)
Figure 19. Global Pancreatic Endocrine Tumor Drug Sales Market Share by Region (2023-2028)
Figure 20. North America Pancreatic Endocrine Tumor Drug Sales YoY (2017-2028) & (K Pcs)
Figure 21. North America Pancreatic Endocrine Tumor Drug Revenue YoY (2017-2028) & (US$ Million)
Figure 22. Europe Pancreatic Endocrine Tumor Drug Sales YoY (2017-2028) & (K Pcs)
Figure 23. Europe Pancreatic Endocrine Tumor Drug Revenue YoY (2017-2028) & (US$ Million)
Figure 24. Asia-Pacific Pancreatic Endocrine Tumor Drug Sales YoY (2017-2028) & (K Pcs)
Figure 25. Asia-Pacific Pancreatic Endocrine Tumor Drug Revenue YoY (2017-2028) & (US$ Million)
Figure 26. Latin America Pancreatic Endocrine Tumor Drug Sales YoY (2017-2028) & (K Pcs)
Figure 27. Latin America Pancreatic Endocrine Tumor Drug Revenue YoY (2017-2028) & (US$ Million)
Figure 28. Middle East & Africa Pancreatic Endocrine Tumor Drug Sales YoY (2017-2028) & (K Pcs)
Figure 29. Middle East & Africa Pancreatic Endocrine Tumor Drug Revenue YoY (2017-2028) & (US$ Million)
Figure 30. The Pancreatic Endocrine Tumor Drug Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
Figure 31. The Top 5 and 10 Largest Manufacturers of Pancreatic Endocrine Tumor Drug in the World: Market Share by Pancreatic Endocrine Tumor Drug Revenue in 2021
Figure 32. Global Pancreatic Endocrine Tumor Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
Figure 33. Global Pancreatic Endocrine Tumor Drug Sales Market Share by Type (2017-2028)
Figure 34. Global Pancreatic Endocrine Tumor Drug Revenue Market Share by Type (2017-2028)
Figure 35. Global Pancreatic Endocrine Tumor Drug Sales Market Share by Application (2017-2028)
Figure 36. Global Pancreatic Endocrine Tumor Drug Revenue Market Share by Application (2017-2028)
Figure 37. North America Pancreatic Endocrine Tumor Drug Sales Market Share by Type (2017-2028)
Figure 38. North America Pancreatic Endocrine Tumor Drug Revenue Market Share by Type (2017-2028)
Figure 39. North America Pancreatic Endocrine Tumor Drug Sales Market Share by Application (2017-2028)
Figure 40. North America Pancreatic Endocrine Tumor Drug Revenue Market Share by Application (2017-2028)
Figure 41. North America Pancreatic Endocrine Tumor Drug Sales Share by Country (2017-2028)
Figure 42. North America Pancreatic Endocrine Tumor Drug Revenue Share by Country (2017-2028)
Figure 43. U.S. Pancreatic Endocrine Tumor Drug Revenue (2017-2028) & (US$ Million)
Figure 44. Canada Pancreatic Endocrine Tumor Drug Revenue (2017-2028) & (US$ Million)
Figure 45. Europe Pancreatic Endocrine Tumor Drug Sales Market Share by Type (2017-2028)
Figure 46. Europe Pancreatic Endocrine Tumor Drug Revenue Market Share by Type (2017-2028)
Figure 47. Europe Pancreatic Endocrine Tumor Drug Sales Market Share by Application (2017-2028)
Figure 48. Europe Pancreatic Endocrine Tumor Drug Revenue Market Share by Application (2017-2028)
Figure 49. Europe Pancreatic Endocrine Tumor Drug Sales Share by Country (2017-2028)
Figure 50. Europe Pancreatic Endocrine Tumor Drug Revenue Share by Country (2017-2028)
Figure 51. Germany Pancreatic Endocrine Tumor Drug Revenue (2017-2028) & (US$ Million)
Figure 52. France Pancreatic Endocrine Tumor Drug Revenue (2017-2028) & (US$ Million)
Figure 53. U.K. Pancreatic Endocrine Tumor Drug Revenue (2017-2028) & (US$ Million)
Figure 54. Italy Pancreatic Endocrine Tumor Drug Revenue (2017-2028) & (US$ Million)
Figure 55. Russia Pancreatic Endocrine Tumor Drug Revenue (2017-2028) & (US$ Million)
Figure 56. Asia Pacific Pancreatic Endocrine Tumor Drug Sales Market Share by Type (2017-2028)
Figure 57. Asia Pacific Pancreatic Endocrine Tumor Drug Revenue Market Share by Type (2017-2028)
Figure 58. Asia Pacific Pancreatic Endocrine Tumor Drug Sales Market Share by Application (2017-2028)
Figure 59. Asia Pacific Pancreatic Endocrine Tumor Drug Revenue Market Share by Application (2017-2028)
Figure 60. Asia Pacific Pancreatic Endocrine Tumor Drug Sales Share by Region (2017-2028)
Figure 61. Asia Pacific Pancreatic Endocrine Tumor Drug Revenue Share by Region (2017-2028)
Figure 62. China Pancreatic Endocrine Tumor Drug Revenue (2017-2028) & (US$ Million)
Figure 63. Japan Pancreatic Endocrine Tumor Drug Revenue (2017-2028) & (US$ Million)
Figure 64. South Korea Pancreatic Endocrine Tumor Drug Revenue (2017-2028) & (US$ Million)
Figure 65. India Pancreatic Endocrine Tumor Drug Revenue (2017-2028) & (US$ Million)
Figure 66. Australia Pancreatic Endocrine Tumor Drug Revenue (2017-2028) & (US$ Million)
Figure 67. Taiwan Pancreatic Endocrine Tumor Drug Revenue (2017-2028) & (US$ Million)
Figure 68. Indonesia Pancreatic Endocrine Tumor Drug Revenue (2017-2028) & (US$ Million)
Figure 69. Thailand Pancreatic Endocrine Tumor Drug Revenue (2017-2028) & (US$ Million)
Figure 70. Malaysia Pancreatic Endocrine Tumor Drug Revenue (2017-2028) & (US$ Million)
Figure 71. Philippines Pancreatic Endocrine Tumor Drug Revenue (2017-2028) & (US$ Million)
Figure 72. Latin America Pancreatic Endocrine Tumor Drug Sales Market Share by Type (2017-2028)
Figure 73. Latin America Pancreatic Endocrine Tumor Drug Revenue Market Share by Type (2017-2028)
Figure 74. Latin America Pancreatic Endocrine Tumor Drug Sales Market Share by Application (2017-2028)
Figure 75. Latin America Pancreatic Endocrine Tumor Drug Revenue Market Share by Application (2017-2028)
Figure 76. Latin America Pancreatic Endocrine Tumor Drug Sales Share by Country (2017-2028)
Figure 77. Latin America Pancreatic Endocrine Tumor Drug Revenue Share by Country (2017-2028)
Figure 78. Mexico Pancreatic Endocrine Tumor Drug Revenue (2017-2028) & (US$ Million)
Figure 79. Brazil Pancreatic Endocrine Tumor Drug Revenue (2017-2028) & (US$ Million)
Figure 80. Argentina Pancreatic Endocrine Tumor Drug Revenue (2017-2028) & (US$ Million)
Figure 81. Middle East and Africa Pancreatic Endocrine Tumor Drug Sales Market Share by Type (2017-2028)
Figure 82. Middle East and Africa Pancreatic Endocrine Tumor Drug Revenue Market Share by Type (2017-2028)
Figure 83. Middle East and Africa Pancreatic Endocrine Tumor Drug Sales Market Share by Application (2017-2028)
Figure 84. Middle East and Africa Pancreatic Endocrine Tumor Drug Revenue Market Share by Application (2017-2028)
Figure 85. Middle East and Africa Pancreatic Endocrine Tumor Drug Sales Share by Country (2017-2028)
Figure 86. Middle East and Africa Pancreatic Endocrine Tumor Drug Revenue Share by Country (2017-2028)
Figure 87. Turkey Pancreatic Endocrine Tumor Drug Revenue (2017-2028) & (US$ Million)
Figure 88. Saudi Arabia Pancreatic Endocrine Tumor Drug Revenue (2017-2028) & (US$ Million)
Figure 89. U.A.E Pancreatic Endocrine Tumor Drug Revenue (2017-2028) & (US$ Million)
Figure 90. Pancreatic Endocrine Tumor Drug Value Chain
Figure 91. Pancreatic Endocrine Tumor Drug Production Process
Figure 92. Channels of Distribution
Figure 93. Distributors Profiles
Figure 94. Bottom-up and Top-down Approaches for This Report
Figure 95. Data Triangulation
Figure 96. Key Executives Interviewed

以下、関連資料のご紹介

転移性メラノーマ治療薬のグローバル市場インサイト・予測（～2028年）

Global Metastatic Melanoma Drug Market Insights and Forecast to 2028
QY2203B12437 2022年3月 107Pages
新型コロナウイルス感染症のパンデミックにより、世界の転移性メラノーマ治療薬の市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に転移性メラノ...

植物薬のグローバル市場インサイト・予測（～2028年）

Global Botanical Drug Market Insights and Forecast to 2028
QY2203B11006 2022年3月 119Pages
新型コロナウイルス感染症のパンデミックにより、世界の植物薬の市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に植物薬の世界市場のxxx％を占...

フィブリノゲン欠乏症治療薬のグローバル市場インサイト・予測（～2028年）

Global Fibrinogen Deficiency Drug Market Insights and Forecast to 2028
QY2203B05315 2022年3月 99Pages
新型コロナウイルス感染症のパンデミックにより、世界のフィブリノゲン欠乏症治療薬の市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年にフィブリノ...

注射用薬物送達システムのグローバル市場インサイト・予測（～2028年）

Global Injectable Drug Delivery Systems Market Insights, Forecast to 2028
QY2203B12156 2022年3月 109Pages
新型コロナウイルス感染症のパンデミックにより、世界の注射用薬物送達システムの市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に注射用薬物送達...

カスパーゼ8のグローバル市場インサイト・予測（～2028年）

Global Caspase 8 Market Insights and Forecast to 2028
QY2203B02252 2022年3月 73Pages
新型コロナウイルス感染症のパンデミックにより、世界のカスパーゼ8の市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年にカスパーゼ8の世界市場の...

徐放性薬物送達システムのグローバル市場インサイト・予測（～2028年）

Global Sustained Release Drug Delivery Systems Market Insights, Forecast to 2028
QY2203B10774 2022年3月 129Pages
新型コロナウイルス感染症のパンデミックにより、世界の徐放性薬物送達システムの市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に徐放性薬物送達...

グルタミルアミノペプチダーゼのグローバル市場インサイト・予測（～2028年）

Global Glutamyl Aminopeptidase Market Insights and Forecast to 2028
QY2203B02638 2022年3月 72Pages
新型コロナウイルス感染症のパンデミックにより、世界のグルタミルアミノペプチダーゼの市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年にグルタミ...

非薬用リップ製品のグローバル市場インサイト・予測（～2028年）

Global Non-Medicated Lip Products Market Insights, Forecast to 2028
QY2203B13458 2022年3月 89Pages
新型コロナウイルス感染症のパンデミックにより、世界の非薬用リップ製品の市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に非薬用リップ製品の世...

抗TIGIT抗体のグローバル市場インサイト・予測（～2028年）

Global Anti-TIGIT Antibody Market Insights and Forecast to 2028
QY2203B09199 2022年3月 107Pages
新型コロナウイルス感染症のパンデミックにより、世界の抗TIGIT抗体の市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に抗TIGIT抗体の世...

1,5-ジフェニルカルバゾンのグローバル市場インサイト・予測（～2028年）

Global 1,5-Diphenyl Carbazone Market Insights, Forecast to 2028
QY2203B00036 2022年3月 91Pages
新型コロナウイルス感染症のパンデミックにより、世界の1,5-ジフェニルカルバゾンの市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に1,5-...

注射用薬物送達システムのグローバル市場インサイト・予測（～2028年） Injectable drug delivery is defined as introduction of a drug or drugs in the patient by using a delivery device. Injectables allow the transport of drugs formulated in liquid form, directly in the body. Even though, they may be designed to transport the drug to specific part of the body. Market Ana…
カスパーゼ8のグローバル市場インサイト・予測（～2028年） Market Analysis and Insights: Global Caspase 8 Market Due to the COVID-19 pandemic, the global Caspase 8 market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic chan…
徐放性薬物送達システムのグローバル市場インサイト・予測（～2028年） Sustained Release Drug Delivery System (SRDDS) is designed to release a drug at a predetermined rate by maintaining a constant drug level for a specific period of time with minimum side effects. Market Analysis and Insights: Global Sustained Release Drug Delivery Systems Market Due to the COVID-19 p…
ヒト成長ホルモン欠乏症 (GHD) 治療薬のグローバル市場 2021年：企業別、地域別、種類・用途別 The Human Growth Hormones Deficiency (Ghd) Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimiz…
球状セルロースアセテートのグローバル市場インサイト・予測（～2028年） Market Analysis and Insights: Global Spherical Cellulose Acetate Market Due to the COVID-19 pandemic, the global Spherical Cellulose Acetate market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast perio…